What Is Pharmacovigilance?
The Complete Guide to Drug Safety
Everything life science teams need to know about pharmacovigilance: the end-to-end process, global regulatory expectations, the technology that powers it, and how to build a safety system that is efficient, compliant, and inspection-ready.
Pharmacovigilance in brief
Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problem. In practice, it is the system pharmaceutical companies, regulators, and public health bodies use to monitor the safety of medicinal products throughout their entire lifecycle, from clinical trials to post-marketing.
- Why it matters: it protects patients and maintains the benefit-risk balance of every product.
- Who requires it: marketing authorization holders and sponsors, under regulations such as EU GVP, FDA requirements, and ICH guidelines.
- What it includes: case intake and processing, signal detection, benefit-risk management, aggregate reporting, and risk minimization.
Why Pharmacovigilance Matters
No clinical trial program can reveal every risk. Trials involve limited, carefully selected populations over defined timeframes, so rare, long-latency, or population-specific adverse reactions often only emerge once a product is used in real-world practice. Pharmacovigilance closes that gap by continuously collecting, evaluating, and acting on safety data.
For life science companies, a robust PV system delivers three things at once:
- Patient safety – early identification and mitigation of emerging risks.
- Regulatory compliance – timely, accurate reporting that stands up to audits and inspections.
- Commercial protection – evidence-based benefit-risk decisions that safeguard product value across the lifecycle.
As data volumes grow and regulatory expectations intensify, pharmacovigilance has shifted from a compliance function to a strategic capability, one that increasingly depends on the right combination of scientific expertise and technology.
The Pharmacovigilance Lifecycle
Pharmacovigilance is a connected set of activities. Weakness at any stage affects everything downstream, which is why leading organizations manage it as a single, integrated safety ecosystem.
Capturing adverse events, medical information, and product quality data from every source, then managing follow-up.
Data entry, coding, medical review, and expedited submission of Individual Case Safety Reports (ICSRs), including literature screening.
Identifying, validating, and prioritizing potential new risks or changes to known risks using statistical and clinical methods.
Evaluating whether a product’s benefits continue to outweigh its risks as new evidence emerges.
Periodic safety reports such as PSURs/PBRERs and DSURs that summarize the evolving safety profile for regulators.
Risk Management Plans (RMPs), REMS, and additional measures that reduce risk and protect patients in practice.
The Global Pharmacovigilance Regulatory Landscape
Pharmacovigilance obligations vary by market, but they share a common foundation in international harmonization. Companies operating globally must satisfy multiple frameworks simultaneously.
| Framework | Region | What it governs |
|---|---|---|
|
Good Pharmacovigilance Practice (GVP) |
European Union |
The EMA’s modular guidance covering PV systems, the PSMF, signal management, PSURs, risk management, and inspections. |
|
EudraVigilance |
European Union |
The EU system for electronic reporting and analysis of suspected adverse reactions. |
|
FDA safety reporting requirements |
United States |
Pre- and post-marketing adverse event reporting, plus REMS where required. |
|
MHRA requirements |
United Kingdom |
UK-specific PV obligations, including the UK QPPV and PSMF. |
|
ICH E2 guidelines |
International |
Harmonized standards for safety data management, including E2B(R3) electronic transmission, E2C(R2) PBRERs, and E2E PV planning. |
Staying compliant requires ongoing regulatory intelligence, a maintained Pharmacovigilance System Master File, and qualified oversight. Qinecsa’s Quality & Compliance services cover PV audit-as-a-service, QPPV services, and EudraVigilance and PSMF setup and maintenance.
Technology in Pharmacovigilance
Manual, fragmented processes cannot keep pace with today’s safety data volumes. Modern pharmacovigilance relies on platforms that standardize intake, automate case workflows, and apply advanced analytics to signal detection, while integrating with, rather than replacing, existing safety ecosystems.
INTAKE
Reportum
A unified, direct-from-source SaaS technology that standardizes and streamlines the initial capture and follow-up of adverse events, medical information, and product quality data.
SAFETY PLATFORM
HaloPV
A modular pharmacovigilance platform that integrates with existing ecosystems. Deploy it as a full lifecycle solution or use targeted capabilities within your PV processes.
Explore HaloPV →SIGNAL DETECTION
Vigilance Workbench (QVW)
A single, feature-rich, integrated platform for signal detection and management, built by pioneers in advanced safety signalling and trusted by top 10 global pharma.
Pharmacovigilance Services and Outsourcing
Case Management
ICSR management, literature screening, medical review, data migration, and submissions.
Signal and Risk Management
Signal detection and management, benefit-risk management (RMP, REMS), and drug safety physician services.
Clinical Safety Management
SAE and SUSAR workflows, drug safety training, and safety management plan development.
Medical Writing
Aggregate reports, protocol review, and risk management reports.
Quality and Compliance
PV audit-as-a-service, QPPV services, and EudraVigilance and PSMF setup and maintenance.
PV Consulting
PV management consulting, benchmarking, regulatory intelligence, and training.
Heathcare Analytics
Advancing signal detection science and delivering complex analyses for public health and regulatory agencies.
Medical Information
Call Center
A 24/7 multilingual call center for intake and follow-up, including FAQ design and maintenance.
How to Build an Inspection-Ready Pharmacovigilance System
Whether you are launching your first product or consolidating a global portfolio, these are the foundations regulators expect to see:
-
A current PSMF that accurately describes your PV system, vendors, and oversight.
-
Qualified oversight, including a QPPV (and local contacts) where required.
-
Documented, validated processes for intake, case processing, and submissions.
-
A structured signal management process with clear validation, prioritization, and decision records.
-
Timely aggregate reporting aligned to regulatory calendars.
-
Vendor and partner oversight backed by quality agreements and KPIs.
-
Regular audits and training to demonstrate continuous improvement.
Not sure where your gaps are? Our PV benchmarking and consulting team can assess your current system against regulatory expectations and industry practice.
Pharmacovigilance FAQs
To protect patients by detecting, assessing, understanding, and preventing adverse effects and other medicine-related problems, ensuring that a product's benefits continue to outweigh its risks throughout its lifecycle.
The terms are often used interchangeably. Drug safety typically refers to the operational handling of safety data, such as case processing, while pharmacovigilance is the broader discipline that also covers signal detection, benefit-risk evaluation, and risk minimization.
An Individual Case Safety Report (ICSR) documents a suspected adverse reaction in a single patient. ICSRs are the core data unit of pharmacovigilance and are exchanged electronically with regulators using the ICH E2B(R3) standard.
A signal is information suggesting a new potential causal association, or a new aspect of a known association, between a medicine and an adverse event that warrants further investigation.
The Qualified Person Responsible for Pharmacovigilance (QPPV) is accountable for establishing and maintaining a marketing authorization holder's PV system in the EU, and is a required role for products authorized there.
Outsourcing can provide specialist expertise, scalable capacity, and access to proven technology. The marketing authorization holder always remains accountable, so strong vendor oversight and clear quality agreements are essential.
Your Specialist Partner for Technology-Enabled Drug Safety
Qinecsa brings together best-in-class technology and scientific expertise to help life science companies stay ahead in an evolving regulatory landscape.
